Mar 17, 2026 · Library of Congress
Introduced in House
Cosponsors
2
Actions
3
Roll calls
0
Amendments
0
Related bills
0
Actions
Mar 17, 2026 · Library of Congress
Introduced in House
Mar 17, 2026 · House floor actions
Referred to the House Committee on Energy and Commerce.
Latest activity
Activity
Lobbying reported · Pharmaceutical Research and Manufacturers of America (PhRMA) · Jul 20
Pharmaceutical Research and Manufacturers of America (PhRMA) reported 2nd Quarter (Apr 1 - June 30) lobbying for Pharmaceutical Research and Manufacturers of America (PhRMA) — $7,360,000
BillsH.Con.Res. 14H.R. 1H.R. 4H.R. 1262H.R. 1492H.R. 3160H.R. 3269H.R. 3521H.R. 4121H.R. 4317H.R. 4570H.R. 4780H.R. 5304H.R. 5342H.R. 5371H.R. 6089H.R. 6423H.R. 6485H.R. 6610H.R. 6624H.R. 6938H.R. 7148H.R. 7837H.R. 7953H.R. 8269H.R. 8646H.R. 8800H.R. 8845H.R. 9102H.R. 9142H.R. 9260H.R. 9310H.R. 9661H.Res. 566S. 2S. 43S. 355S. 652S. 832S. 864S. 1040S. 1071S. 1096S. 1387S. 1546S. 1553S. 1954S. 2256S. 2296S. 2354S. 2587S. 2620S. 2658S. 3014S. 3345S. 3452S. 3788S. 4784
Lobbying reported · Aviva Strategies · Jul 17
Aviva Strategies reported 2nd Quarter (Apr 1 - June 30) lobbying for Endeavor Biomedicines — $51,000
BillsH.R. 7953
Lobbying reported · Glaxosmithkline · Jul 16
Glaxosmithkline reported 2nd Quarter (Apr 1 - June 30) lobbying for Glaxosmithkline — $890,000
BillsH.Con.Res. 14H.R. 1H.R. 4H.R. 1262H.R. 1492H.R. 3160H.R. 3269H.R. 3521H.R. 4121H.R. 4317H.R. 4570H.R. 4780H.R. 5304H.R. 5342H.R. 5509H.R. 6423H.R. 6485H.R. 6610H.R. 6624H.R. 6938H.R. 7148H.R. 7391H.R. 7837H.R. 7953H.R. 8269H.R. 8646H.R. 8800H.R. 8845H.R. 9102H.R. 9142H.R. 9260H.R. 9310H.Res. 566S. 2S. 43S. 355S. 652S. 832S. 864S. 891S. 1040S. 1071S. 1096S. 1546S. 1553S. 1954S. 2256S. 2296S. 2354S. 2587S. 2620S. 2658S. 3014S. 3345S. 3452S. 3788S. 4784
You’re all caught up.